Acoustic Stimulation, Sleep, and Cognitive-Emotional Processes in Young Adults With Anxiet
In this study, the investigators will recruit young adults (ages 18-25 years) with elevated anxiety/depression symptoms and sleep disturbance. Participants will complete two overnights in a sleep lab. During one of the overnights, slow-wave activity will be enhanced by delivering sub-arousal auditory tones during slow-
| Condition(s) | Acoustic Stimulation |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | In this study, the investigators will recruit young adults (ages 18-25 years) with elevated anxiety/depression symptoms and sleep disturbance. Participants will complete two overnights in a sleep lab. During one of the overnights, slow-wave activity will be enhanced by delivering sub-arousal auditory tones during slow-wave sleep using a headband device (Philips SmartSleep or Dreem 2). During the other overnight, tones will not be administered. Cognitive and emotional processes will be evaluated using behavioral task performance, self-report, and functional magnetic resonance imaging (fMRI). After the second overnight, participants will take the headband device home and wear it every night for approximately 2 weeks. For half of the participants, the headband will play tones every night and, |
| Who can participate | Inclusion Criteria: 1. Age 18-25. Equal numbers of men and women will be included. 2. Normal hearing. 3. Elevated anxiety or depression symptoms. This will be determined using the PROMIS anxiety and PROMIS depression scales. Participants with T-scores ≥ 60 (i.e., ≥ than 1 standard deviation above the mean) on either or both scales will be eligible for participation. 4. Elevated sleep disturbance. This will be determined using the PROMIS sleep disturbance scale. Participants with T-scores ≥ 55 on the PROMIS sleep disturbance scale will be eligible for participation. Exclusion Criteria: 1. Presence of a severe chronic or psychiatric condition including psychosis, bipolar disorder, developmental disorders, or substance use disorder. 2. Current use of psychotropic medications or medications af |
| Ages | 18 Years to 25 Years |
| Sex | All |
| Lead sponsor | Michelle Stepan |
| Locations | Pittsburgh, Pennsylvania, United States |
| Start date | 2024-04-24 |
| NCT ID | NCT05802004 |
| Official listing | https://clinicaltrials.gov/study/NCT05802004 |